$TNDM News

Tandem Diabetes Care Q2 2026 Earnings Call Transcript

Barclays Initiates Coverage On Tandem Diabetes Care with Equal-Weight Rating, Announces Price Target of $18

Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026

Q2 Earnings Highlights: Tandem Diabetes (NASDAQ:TNDM) Vs The Rest Of The Healthcare Technology Stocks

Citigroup Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $20

Is Tandem Diabetes Care (TNDM) Undervalued As Investors Weigh Its 34% One Year Return?

Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?

Tandem Diabetes Care: Stop Paying For Tomorrow's Profits - Strong Sell

3 Reasons TNDM is Risky and 1 Stock to Buy Instead

William Blair Initiates Coverage On Tandem Diabetes Care with Outperform Rating

Tandem Diabetes Care Maps Growth Plan With Pharmacy Shift and Tubeless Mobi

5 Must-Read Analyst Questions From Tandem Diabetes’s Q2 Earnings Call

Tandem Diabetes (TNDM) Q2 2026 Earnings Call Transcript

TNDM Q2 Loss Narrower Than Expected, Revenues Miss, Stock Up

Why Tandem Diabetes (TNDM) Stock Is Trading Up Today

TNDM Q2 Deep Dive: Pharmacy Channel Gains and Pipeline Execution Amid Margin Recovery

Why Tandem Diabetes Care (TNDM) Is Up 14.8% After Record Q2 Sales And PayGo Momentum

Tandem Diabetes Care (TNDM) Could Be 23% Below Fair Value After Q2 Results

Tandem Diabetes Care's Underlying Q2 Trends Better Than Headline Suggests, RBC Says

Tandem Diabetes Care Q2 Earnings Call Highlights